| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8487093 | MSD MERCK CO | β-lactamase inhibitors |
Nov, 2029
(5 years from now) | |
Recarbrio is owned by Msd Merck Co.
Recarbrio contains Cilastatin Sodium; Imipenem; Relebactam.
Recarbrio has a total of 1 drug patent out of which 0 drug patents have expired.
Recarbrio was authorised for market use on 16 July, 2019.
Recarbrio is available in powder;intravenous dosage forms.
Recarbrio can be used as treatment of complicated urinary tract infections, including pyelonephritis (cuti).
Drug patent challenges can be filed against Recarbrio from 16 July, 2028.
The generics of Recarbrio are possible to be released after 19 November, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 16, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Jul 16, 2029 |
Drugs and Companies using CILASTATIN SODIUM; IMIPENEM; RELEBACTAM ingredient
NCE-1 date: 16 July, 2028
Market Authorisation Date: 16 July, 2019
Treatment: Treatment of complicated urinary tract infections, including pyelonephritis (cuti)
Dosage: POWDER;INTRAVENOUS
RECARBRIO family patents
